Skip to main content

Celera Grants Bayer Cancer Rx License; Retains Companions Dx Rights

NEW YORK (GenomeWeb News) – Celera today said that it has licensed exclusive worldwide rights to Bayer Schering Pharma for five cancer-related drug targets and associated in vivo diagnostic imaging.

The Alameda, Calif.-based molecular diagnostics firm said that it will retain in vitro diagnostic rights and will be able to develop and sell companion diagnostics specific to therapeutic compounds developed by Bayer under the deal.

Celera said that the therapeutic targets are over-expressed on the surface of several different tumor cell types and were identified using its proteomics discovery platform.

Bayer Schering Pharma will pay Celera a one-time fee for the exclusive rights to the five targets. It also will make additional milestone payments based on development and commercialization goals, and it also will pay royalties to Celera based on product sales.

Steve Rubin, vice president of proteomic research at Celera, said that the deal allows Celera "the flexibility to advance part of our broad pipeline of validated targets for additional future value."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.